Findings

What do systematic reviews say?

7 questions · 8 findings · 1 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 37.5%Moderate 3 · 37.5%High 0 · 0%

Rituximab vs placebo or control

Relapse at 3 months · SSNS in children

Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.32 [0.14, 0.7]
3 studies · 132 participants
Moderate

Rituximab vs placebo or control

Relapse · SSNS in children

Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).

2 findings from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.23 [0.12, 0.43]
5 studies · 269 participants
Moderate
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.63 [0.42, 0.93]
3 studies · 198 participants
Moderate

Rituximab vs placebo or control

Frequent relapses · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs placebo or control

Mean relapse rate/patient/month · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs placebo or control

Adverse effects: moderate to severe Infusion reactions · SSNS in children

Rituximab may leads to higher adverse effects: moderate to severe Infusion reactions compared with placebo or control (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 5.83 [1.34, 25.29]
4 studies · 252 participants
Low

Rituximab vs placebo or control

Adverse effects: severe infection · SSNS in children

Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.9 [0.26, 3.15]
3 studies · 222 participants
Low

Rituximab vs placebo or control

Adverse effects: arthropathy · SSNS in children

Rituximab showed no clear difference in adverse effects: arthropathy compared with placebo or control (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 3.92 [0.45, 33.98]
2 studies · 84 participants
Low